The efficacy of ethylmethylhydroxypyridine in the rehabilitation treatment of poststroke patients
Author:
O.V. M.V. ZHURAVLEVA1,2, A.B. PROKOFIEV1,2, V.V. ARKHIPOV1, S.YU. SEREBROVA1,2, G.I. GORODETSKAY1,2, O.A. DEMIDOVA1
1 Research center for examination of medical devices, Moscow, Russia
2 Sechenov First Moscow state medical University (Sechenov University), Moscow, Russia
Summary:
The analysis of the clinical efficacy and safety of ethylmethylhydroxypyridine succinate (mexidol) in the complex of rehabilitation measures in patients after ischemic stroke (IS) shows that course treatment with mexidol improves the recovery of neurological functions, decreases neurological deficit, cognitive disorders, including memory impairment, and manifestations of asthenic syndrome, increases the level of social adaptation and improves the psycho-emotional state of patients, reduces spasticity, increases motor and speech activity, praxis, reliably eliminates the ignoring syndrome. There is a decrease in the level of total cholesterol and low-density b-lipoproteins in the blood, and decrease in the severity of hypercoagulation. The results of the studies have convincingly shown the efficacy of mexidol at all stages of rehabilitation treatment of patients with IS.
Keywords: ethylmethylhydroxypyridine succinate, mexidol, rehabilitation, recovery, stroke.
Efficacy and safety of the drug Mexidol forte 250 as part of long-term sequential therapy in patients with carotid stroke
Author:
I.A. STRELNIKOVA1, A.A. SVETKINA1,2, O.V. ANDROFAGINA1
1 Samara Regional Clinical Hospital named after V.D. Seredavina, Samara, Russia;
2 Samara State Medical University, Samara, Russia
Summary:
Objective. To evaluate an effect of long-term sequential therapy with mexidol and mexidol forte on the functional outcome of patients with carotid ischemic stroke. Material and methods. The study included 50 patients with newly developed carotid stroke, hospitalized in the stroke unit on the first day from the onset of the disease. Patients of the main group (n=25) received mexidol in a dose of 500 mg intravenously once a day for 14 days, then mexidol forte 250 in tabs 250 mg 3 times a day for 60 days. Patients of the comparison group (n=25) received standard basic therapy. The significance of intergroup differences was assessed using the Mann—Whitney test, Fisher’s exact test, and relative risk (OR) calculation. Differences were considered significant at a level of p<0,05. Results. After 14 days of therapy, both groups of patients showed a positive trend compared to baseline. At the same time, patients of the mexidol group had a higher MoCA score (U=173,5, p=0,006), a lower score when performing tasks on dynamic praxis (U=214,0, p=0,028) and optical spatial disturbances (U=170,5, p=0,003), better memorization strength (181,5, p = 0,006) and better performance on abstraction MOCA subtest (U=200,5, p=0,014). By the 74th day, the absence of moderate cognitive impairment (MoCA> 26 points) was diagnosed in 17 patients (68%) of the main group and 14 patients (56%) of the comparison group. No significant differences were found. Moreover, patients of the main group had a significantly lower NIHSS score (U=124,0, p<0,001) and a lower degree of disability: a total mRS score 0—2 was achieved in 19 (76%) patients of the main group and only in 12 (48%) patients of the comparison group (OR=3,34, F=0,07, p<0,05). Also, patients receiving long-term sequential therapy with mexidol and mexidol forte 250 had milder spatial disorders than patients of the comparison group. Conclusion. Consecutive treatment with mexidol and mexidol forte 250 in the acute and early recovery periods of ischemic stroke positively affects the regression of local neurological symptoms, increases the likelihood of achieving independence in everyday life by 3,34 times, and reduces the severity of optical-spatial, neurodynamic and memory impairments.
Keywords: ischemic stroke, mexidol, mexidol forte 250, cognitive impairment, functional outcome.
Efficacy and safety of the drug Mexidol forte 250 as part of long-term sequential therapy in patients with carotid stroke
This article is in "Library" section.
Author:
I.A. STRELNIKOVA1, A.A. SVETKINA1,2, O.V. ANDROFAGINA1
1 Samara Regional Clinical Hospital named after V.D. Seredavina, Samara, Russia;
2 Samara State Medical University, Samara, Russia
Possibility of application Mexidol for the treatment of patients suffering from sensorineural hearing loss and cerebrovascular insufficiency
This article is in "Library" section.
Author:
N.L. KUNELSKAYA1, 2, YU.V. LEVINA1, 2, E.S. YANYUSHKINA1, D.S. OGORODNIKOV1, 2, E.V. LARIONOVA1
1 L.I. Sverzhevskiy Research Institute of Clinical Otorhinolaryngology, Moscow Health Department, Moscow, Russia, 117152;
2 Department of Otorhinolaryngology N.I.Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia,117997
Possibility of application Mexidol for the treatment of patients suffering from sensorineural hearing loss and cerebrovascular insufficiency
Author:
N.L. KUNELSKAYA1, 2, YU.V. LEVINA1, 2, E.S. YANYUSHKINA1, D.S. OGORODNIKOV1, 2, E.V. LARIONOVA1
1 L.I. Sverzhevskiy Research Institute of Clinical Otorhinolaryngology, Moscow Health Department, Moscow, Russia, 117152;
2 Department of Otorhinolaryngology N.I.Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia,117997
Summary:
Sensorineural hearing loss can develop as a consequence of vascular pathology. The etiology and pathogenesis of chronic sensorineural hearing loss allow us to consider promising the use of neuroprotective drugs in the treatment regimen that can activate the function of the neural structures of the auditory pathway. Ethylmethylhydroxypyridine succinate, having complex pharmacological capabilities and a wide range of effects realized at the neural and vascular levels can be used in the treatment of hearing impairment and speech intelligibility.
Keywords: hearing loss, sensorineural hearing loss, rehabilitation of auditory function, Ethylmethylhydroxypyridine succinate.
The study of the efficacy and safety of Mexidol and Mexidol Forte in patients with chronic cerebral ischemia
Author:
V.A. KUTASHOV, O. V. ULYANOVA
Voronezh State Medical University. N.N. Burdenko, Voronezh, Russia
Summary:
Objective. To study the efficacy and safety of Mexidol used intravenously (500 mg 1 time per day) for 14 days, followed by the oral administration of Mexidol Forte 250 in a dose of 250 mg 3 times a day for 60 days, in patients with chronic cerebral ischemia (CCI). Material and methods. The study included 56 patients with CCI due to a combination of hypertension and atherosclerosis. The results of physical examinations (control of blood pressure, heart rate etc.), dynamics of complaints, scores on CGI, MoCa, MFI‑20, HRSD, HARS and the Tinetti test were evaluated. Results and conclusion. The high level of efficacy and safety of intravenous injections of Mexidol followed by the oral administration of Mexidol Forte 250 are demonstrated. This scheme of therapy contributes to a significant decrease in the objective and subjective symptoms of CCI, leads to improvements in the emotional, cognitive and motor spheres.
Keywords: chronic brain ischemia, atherosclerosis, arterial hypertension, motor disorders, cognitive disorders, Mexidol, Mexidol Forte 250.
The study of the efficacy and safety of Mexidol and Mexidol Forte in patients with chronic cerebral ischemia
This article is in "Library" section.
Author:
V.A. KUTASHOV, O. V. ULYANOVA
Voronezh State Medical University. N.N. Burdenko, Voronezh, Russia
Effect of mexidol on physical and mental performance under stressogenic conditions in experiment
This article is in "Library" section.
Author:
I.G. KAPITSA, E.A. IVANOVA, T.A. VORONINA
FSBI «Zakusov Institute of Pharmacology», Moscow
Effect of mexidol on physical and mental performance under stressogenic conditions in experiment
Author:
I.G. KAPITSA, E.A. IVANOVA, T.A. VORONINA
FSBI «Zakusov Institute of Pharmacology», Moscow
Summary:
Resume. The effect of Mexidol on physical performance of mice under the extreme conditions of the weight-loaded forced swim test and on the mental performance of rats under the conditions of a neurosis-like state caused by a functional disturbance of a defensive instrumental conditioned active avoidance reflex was studied. A single dose (50 and 100 mg/kg) or a subchronic regimen (100 mg/kg) of Mexidol administered intrapertoneally enhances the physical performance of mice similarly to mildronate (100 mg/kg). Mexidol improves the rate of operant conditioning, the preservation of the memory trace and its restoration after single or multiple instances of disruption of the conditioned active avoidance reflex, and its effect does not differ from the effect of the comparison drug piracetam (300 mg/kg).
Keywords: performance; learning; memory; functional disturbance.
Improvement of the efficacy of treatment of hypertensive encephalohathy by using mexidol
This article is in "Library" section.
Author:
E.V. BOLOTOVA, N.YU. LUSHPAY, I.V. KOVRIGINA
Kuban State Medical University under the Health Care Ministry of the Russia, Krasnodar, Russia; Reserch Institute — Territorial Clinical
Hospital №1 med after Professor S.V. Ochapovski under the Health Ministry of the Russia, Krasnodar, Russia